Finn Georg Brun Wisløff

• Wisløff, Finn Georg B (2022). Mild demens – ikke begynnende demens. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 142(12). doi: 10.4045/tidsskr.22.0181.
• Wisløff, Finn Georg B (2012). Kvalitet i medisinsk forskning : hva er det? In Larsen, Øivind; Fretheim, Atle; Larsen, Ingegerd Frøyshov & Westin, Steinar (Ed.), Medisinsk kunnskap - Hvor kommer den fra, og hva brukes den til?. Gyldendal Akademisk. ISSN 978-82-05-39912-9. p. 64–76.
• Kvam, Ann Kristin; Fayers, Peter & Wisløff, Finn Georg B (2011). Responsiveness and minimal important score differences in quality-of-life questionnaires: a comparison of the EORTC QLQ-C30 cancer-specific questionnaire to the generic utility questionnaires EQ-5D and 15D in patients with multiple myeloma. European Journal of Haematology. ISSN 0902-4441. 87(4), p. 330–337. doi: 10.1111/j.1600-0609.2011.01665.x.
• Kvam, Ann Kristin; Wisløff, Finn Georg B & Fayers, Peter (2010). Minimal important differences and response shift in health-related quality of life; a longitudinal study in patients with multiple myeloma. Health and Quality of Life Outcomes. ISSN 1477-7525. 8(79). doi: 10.1186/1477-7525-8-79. Full text in Research Archive
• Gimsing, Peter; Carlson, Kristina; Turesson, Ingemar; Fayers, Peter; Waage, Anders & Vangsted, Annette [Show all 22 contributors for this article] (2010). Effect of pamidronate 30mg versus 90mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. The Lancet Oncology. ISSN 1470-2045. 11(10), p. 973–982. doi: 10.1016/S1470-2045(10)70198-4.
• Waage, Anders; Gimsing, P; Fayers, Peter; Abildgaard, N; Ahlberg, L & Bjorkstrand, B [Show all 25 contributors for this article] (2010). Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood. ISSN 0006-4971. 116(9), p. 1405–1412. doi: 10.1182/blood-2009-08-237974.
• Iversen, Per Ole; Wisløff, Finn Georg B & Gulbrandsen, Nina (2010). Reduced nutritional status among multiple myeloma patients during treatment with high-dose chemotherapy and autologous stem cell support. Clinical Nutrition. ISSN 0261-5614. 29(4), p. 488–491. doi: 10.1016/j.clnu.2009.12.002.
• Kvam, Ann K.; Fayers, Peter & Wisløff, Finn (2010). What changes in health-related quality of life matter to multiple myeloma patients? A prospective study. European Journal of Haematology. ISSN 0902-4441. 84(4), p. 345–353. doi: 10.1111/j.1600-0609.2009.01404.x.
• Kvam, AK; Fayers, Peter; Hjermstad, Marianne Jensen; Gulbrandsen, N; Wisloff, F & Wisløff, Finn Georg B (2009). Health-related quality of life assessment in randomised controlled trials in multiple myeloma: a critical review of methodology and impact on treatment recommendations. European Journal of Haematology. ISSN 0902-4441. 83(4), p. 279–289. doi: 10.1111/j.1600-0609.2009.01303.x.
• Dahl, Inger Marie S.; Wisløff, Finn; Børset, Magne & Mella, Olav (2009). Myelomatose, Medikamentell kreftbehandling. Cytostatikaboken. 7Letras. ISSN 978-829923312-5. p. 346–356.
• Aasbrenn, Martin; Langmark, Frøydis & Wisløff, Finn Georg B (2008). Er registreringen av myelomatose i Kreftregisteret god nok? Tidsskrift for Den norske legeforening. ISSN 0029-2001. 128(23).
• Iversen, Per Ole; Ukrainchenko, Ekaterina; Afanasyev, Boris; Hulbekkmo, Kristin; Choukah, Amal & Gulbrandsen, Nina [Show all 8 contributors for this article] (2008). Impaired nutritional status during intensive chemotherapy in Russian and Norwegian cohorts with acute myeloid leukemia. Leukemia and Lymphoma. ISSN 1042-8194. 49(10), p. 1916–1924. doi: 10.1080/10428190802339723.
• Aasbrenn, Martin; Langmark, Frøydis & Wisløff, Finn Georg B (2008). Er registreringen av myelomatose i Kreftregisteret god nok? Tidsskrift for Den norske legeforening. ISSN 0029-2001. 128(23), p. 2712–2714.
• Sandset, Per Morten & Wisløff, Finn Georg B (2007). Blodsykdommer. In Vilberg, Astri (Eds.), Norsk legemiddelhåndbok for helsepersonell 2007. Foreningen for utgivelse av Norsk Legemiddelhåndbok. ISSN 978-82-90732-09-2. p. 147–172.
• Sandset, Per Morten & Wisløff, Finn Georg B (2007). Legemidler ved blodsykdommer. In Vilberg, Astri (Eds.), Norsk legemiddelhåndbok for helsepersonell 2007. Foreningen for utgivelse av Norsk Legemiddelhåndbok. ISSN 978-82-90732-09-2. p. 815–848.
• Sandset, Per Morten & Wisløff, Finn Georg B (2007). Legemidler og bruken av dem. In Nordeng, Hedvig M Egeland & Spigset, Olav (Ed.), Legemidler og bruken av dem. Gyldendal Akademisk. ISSN 978-82-05-32365-0. p. 197–204.
• Wisløff, Finn Georg B; Kvam, Ann Kristin; Hjorth, Martin & Lenhoff, Stig (2007). Serum calcium is an independent predictor of quality of life in multiple myeloma. European Journal of Haematology. ISSN 0902-4441. 78, p. 29–34. doi: 10.1111/j.0902-4441.2006.t01-1-EJH2887.x.
• Liestøl, Sigurd; Sandset, Per Morten; Mowinckel, M.C. & Wisløff, Finn Georg B (2007). Activated protein C resistance determined with a thrombin generation-based test is associated with thrombotic events in patients with lupus anticoagulants. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. 5(11), p. 2204–2211. Show summary

  Background: Several studies suggest that antiphospholipid antibodies interfere with the activity of activated protein C (APC). This acquired form of APC resistance has been proposed as a possible pathogenic mechanism underlying hypercoagulability associated with the antiphospholipid syndrome (APS).Objectives: We wanted to investigate the inhibitory effect of recombinant APC (rAPC) on ex vivo thrombin generation in plasma and the modification of this effect by the presence of lupus anticoagulants (LA).Patients/Methods: We analyzed plasmas from 81 patients with LA (52 patients fulfilling the criteria for the APS) and 91 controls. Percent inhibition of the endogenous thrombin potential (ETP) as a parameter of APC sensitivity was determined in plasmas using a thrombin generation-based APC resistance test probed with rAPC. All results were normalized using pooled normal plasma (PNP) as a reference.Results: Normalized percent inhibition of ETP by APC was lower in patients with LA [61.4%, 95% confidence interval (CI) 45.8-74.5%] compared to controls (107.8%, 95% CI: 107.1-109.3%). In patients with LA and APS, median inhibition was lower than in patients with LA without APS (44.6%, 95% CI: 30.1-55.7% vs. 78.8%, 95% CI: 73.9-95.8%). This difference also persisted when patients on warfarin therapy were excluded from the APS subgroup.Conclusions: APC resistance can be demonstrated with a thrombin generation-based test in a majority of patients with the LA laboratory phenotype. A history of thrombotic events in patients with LA is associated with a stronger resistance to the anticoagulant effect of APC.

• Cocks, K; Cohen, D; Wisløff, Finn Georg B; Sezerc, O; Lee, S & Hippe, E [Show all 15 contributors for this article] (2007). An internadional field study of the reliability and validity of a disease-specfic questionnanire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. European Journal of Cancer. ISSN 0959-8049. 43, p. 1670–1678. doi: 10.1016/j.ejca.2007.04.022.
• Liestøl, Sigurd; Sandset, Per Morten; Jacobsen, Eva Marie; Mowinckel, Marie-Christine & Wisløff, Finn Georg B (2007). Decreased anticoagulant response to tissue factor pathway inhibitor type 1 in plasmas from patients with lupus anticoagulants. British Journal of Haematology. ISSN 0007-1048. 136, p. 131–137. Show summary

  Inhibition of tissue factor pathway inhibitor type 1 (TFPI) is one of the mechanisms by which lupus anticoagulants (LA) may upregulate tissue factor (TF) activity. We wanted to examine whether purified immunoglobulin G (IgG) from patients with LA may interfere with the ability of TFPI to inhibit ex vivo TF-induced thrombin generation. The endogenous thrombin potential (ETP) in pooled normal plasma (PNP) supplemented with IgG from either patients with LA or controls was determined in the absence or presence of recombinant TFPI (rTFPI). In the presence of a heparin neutraliser, the ETP was also determined in plasmas from patients with LA and controls before and after heparin injection in order to quantify the anticoagulant effect of heparin-releasable TFPI in vivo. Compared with IgG from controls (n = 14), IgG from patients with LA (n = 28) induced a wide range of enhancing or inhibitory effects on the ETP in PNP. The response to rTFPI in PNP with IgG from patients with LA correlated inversely with thrombin generation (rs = 0·637, P = 0·0003). Correspondingly, the relative inhibition of ETP in postheparin plasmas was smaller for patients (n = 11) than for controls (n = 9) (32% vs. 68%, P = 0·007). Our findings support the hypothesis that TFPI anticoagulant activity is inhibited in some patients with LA.

• Galli, M; Borrelli, G; Jacobsen, Eva Marie; Marfisi, RM; Marchioli, R & Wisløff, Finn Georg B [Show all 8 contributors for this article] (2007). Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study. Blood. ISSN 0006-4971. 110, p. 1178–1183. Show summary

  To assess the clinical significance of lupus anticoagulants (LAs) and antiphospholipid antibodies (aPLs) toward thrombosis and abortions, we measured them in 112 patients whose samples were available at enrollment in the warfarin in the antiphospholipid syndrome (WAPS) study. Enzyme-linked immunosorbent assay (ELISA) and coagulation test values in the highest and lowest tertiles were compared. When considered separately, IgG antibodies to beta2-glycoprotein I (abeta2GPI) and prothrombin (aPT) were associated with anamnestic arterial and venous thrombosis, respectively, and those to annexin AV (aAnAV) with abortions. IgM antibodies to protein S and the lupus ratio of the dilute prothrombin time were associated with prospective thrombosis. No other association for IgM antibodies was seen. LA-positive patients who carried abeta2GPI antibodies were at risk of anamnestic arterial and total thrombosis and aPT antibodies to that of anamnestic venous and total thrombosis. LA-positive patients who carried IgG abeta2GPI and aAnAV antibodies were at risk for both anamnestic abortion and prospective thrombosis. Overall, these data support the inclusion of abeta2GPI antibodies in and suggest the removal of anticardiolipin antibodies from the laboratory criteria of the antiphospholipid syndrome. They also suggest that the measurement of aPT and aAnAV antibodies is useful in some selected situations and that there is little role for IgM antibody detection.

• Jacobsen, EM; Trettenes, EJ; Wisløff, Finn Georg B & Abildgaard, Ulrich (2006). Detection and quantification of lupus anticoagulants in plasma from heparin treated patients, using addition of polybrene. Thrombosis Journal. ISSN 1477-9560. 4, p. 3–8.
• Lenhoff, Stig; Hjorth, Martin; Turesson, Ingemar; Westin, Jan; Gimsing, Peter & Wisløff, Finn Georg B [Show all 19 contributors for this article] (2006). Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results with focus on the effect of response degree on survival and relapse pattern after transplantation. Studies in Surface Science and Catalysis. ISSN 0167-2991. 91, p. 1228–1233.
• Crowther, MA & Wisløff, Finn Georg B (2005). Evidence based treatment of the anti phospholipid syndrome II. Optimal anticoagulant therapy for thrombosis. Thrombosis Research. ISSN 0049-3848. 115.
• Guren, Tormod Kyrre; Christoffersen, Thoralf; Thoresen, G. Hege; Wisløff, Finn Georg B; Tveit, Magne Kjell & Dajani, Olav (2005). Antitumormidler rettet mot tyrosinkinaser. Tidsskrift for Den norske legeforening. ISSN 0029-2001. p. 3115–3119.
• Wisløff, Finn Georg B; Gulbrandsen, Nina; Hjorth, M; Lenhoff, S & Fayers, P. (2005). Quality of life may be affected more by disease parameters and response to therapy than by haemoglobin changes. European Journal of Haematology. ISSN 0902-4441. 75(4), p. 293–298.
• Finazzi, G; Marchioli, R; Brancaccio, V; Schinco, P; Wisløff, Finn Georg B & Musial, J [Show all 12 contributors for this article] (2005). A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). Journal of Thrombosis and Haemostasis. ISSN 1538-7933. 3(5), p. 848–853.
• Liestøl, Sigurd & Wisløff, Finn Georg B (2005). Effect of subcutaneous administration of dalteparin on lupus anticoagulant assays. Thrombosis Research. ISSN 0049-3848. 115(6), p. 509–517.
• Hippe, E; Westin, J & Wisløff, Finn Georg B (2005). Nordic Myeloma Study Group, the first 15 years: scientific collaboration and improvement of patient care. European Journal of Haematology. ISSN 0902-4441. 74(3), p. 185–193.
• Smith, A; Wisløff, Finn Georg B & Samson, D (2005). Guidelines on the diagnosis and management of multiple myeloma 2005. British Journal of Haematology. ISSN 0007-1048. 132, p. 410–451.
• Wisløff, Finn Georg B & Crowther, M (2004). Evidence-based treatment of the antiphospholipid syndrome I. Pregnancy failure. Thrombosis Research. ISSN 0049-3848. 114, p. 75–81.
• Waage, Anders; Gimsing, Peter; Juliusson, Gunnar; Turesson, Ingemar; Gulbrandsen, Nina & Eriksson, Tommy [Show all 11 contributors for this article] (2004). Early response predicts thalidomide efficiency in patients with advanced multiple myeloma. British Journal of Haematology. ISSN 0007-1048. 125, p. 149–155.
• Waage, Anders; Gimsing, Peter; Juliusson, Gunnar; Turesson, Ingemar; Gulbrandsen, Nina & Eriksson, T [Show all 11 contributors for this article] (2004). Early response predicts thalidomide efficiency in patients with advanced multiple myeloma. British Journal of Haematology. ISSN 0007-1048. 125, p. 149–155.
• Gulbrandsen, Nina; Hjermstad, Marianne Jensen & Wisløff, Finn Georg B (2004). Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences. European Journal of Haematology. ISSN 0902-4441. 72, p. 172–180.
• Hellström-Lindberg, E.; Gulbrandsen, Nina; Lindberg, G.; Ahlgren, T; Dahl, I.M.S. & Dybedal, I. [Show all 15 contributors for this article] (2003). A valdiated dicision model for treating the anaemia of myelodyscplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. British Journal of Haematology. ISSN 0007-1048. 120, p. 1–10.
• Iversen, Per Ole & Wisløff, Finn Georg B (2003). Gauchers sykdom. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 123, p. 304–307.
• Wisløff, Finn Georg B (2003). A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. British Journal of Haematology. ISSN 0007-1048. 120, p. 1037–1046.
• Wisløff, Finn Georg B (2003). Laboratory diagnosis of the antiphospholipid syndrome. Thrombosis Research. ISSN 0049-3848. 108, p. 263–271.
• Wisløff, Finn Georg B; Brinch, Lorentz & Hammerstrøm, Jens (2003). Nasjonalt handlingsprogram for kronisk myelogen leukemi. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 123, p. 157–159.
• Wisløff, Finn; Brinch, Lorentz & Hammerstrøm, Jens (2003). Nasjonalt handlingsprogram for kronisk myelogen leukemi. Tidsskrift for Den norske legeforening. ISSN 0029-2001. p. 157–159. Show summary

  Engelsk sammendrag finnes i artikkelen på: www.tidsskriftet.no

• Evensen, Stein A.; Brinch, Lorentz; Hammerstrøm, Jens; Wisløff, Finn & Waage, Anders (2003). Leukemi hos voksne. Kap. 22. Cytostatikaboken.
• Liestøl, Sigurd; Jacobsen, Eva Marie & Wisløff, Finn Georg B (2002). Dilute prothrombin time-based lupus ratio test. Integrated LA testing with recombinant tissue thromboplastin. Thrombosis Research. ISSN 0049-3848. 105, p. 177–182.
• Standal, T.; Børset, M.; Lenhoff, Stig; Wisløff, Finn Georg B; Stordal, B. & Sundan, Andreas [Show all 8 contributors for this article] (2002). Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor. Blood. ISSN 0006-4971. 100, p. 3925–3929.
• Wisløff, Finn Georg B (2002). Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor. Blood. ISSN 0006-4971. 100, p. 3925–3929.
• Standal, Therese; Børset, Magne; Lenhoff, S.; Wisløff, Finn; Størdal, Berit Fladval & Sundan, Anders [Show all 8 contributors for this article] (2002). Serum insulin-like growth factor is not increased in patients with multiple myelomna but is still a prognostic factor. Blood. ISSN 0006-4971. 100, p. 3925–3929.
• Wisløff, Finn; Brinch, Lorentz & Hammerstrøm, Jens (2002). Handlingsprogram for kronisk myelogen leukemi. Tidsskrift for Den norske legeforening. ISSN 0029-2001.
• Gulbrandsen, Nina; Wisløff, Finn Georg B; Nord, Erik; Lenhoff, Stig; Hjorth, Martin & Westin, Jan (2001). Cost-utility analysis of high dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients <60 years with multiple myeloma. European Journal of Haematology. ISSN 0902-4441. 66, p. 328–336.
• Gulbrandsen, Nina; Wisløff, Finn Georg B; Brinch, Lorentz; Carlson, Kristina; Dahl, Inger Marie & Gimsing, Peter [Show all 16 contributors for this article] (2001). Health-related quality of life in multiple myeloma patients receiving high dose chemotherapy with autologous blood stem cell support. Medical Oncology (MO). ISSN 1357-0560. 18, p. 65–77.
• Wisløff, Finn Georg B; Tangen, Jon-Magnus; Brinch, Lorentz; Dahl, Inger Marie; Gruber, Franz & Hammerstrøm, Jens [Show all 9 contributors for this article] (2001). Høydosebehandling med autolog stamcellestøtte- endelig et fremskritt ved myelomatose. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 121, p. 2402–2406.
• Jacobsen, Eva Marie; Barna-Cler, Linda; Taylor, Michael; Triplett, Douglas & Wisløff, Finn Georg B (2001). The evaluation of clotting times in the laboratory detection of lupus anticogulants. Thrombosis Research. ISSN 0049-3848. 104, p. 275–282.
• Gulbrandsen, Nina; Wisløff, Finn; Brinch, Lorentz; Carlson, K.; Dahl, Inger-Marie & Gimsing, P. [Show all 11 contributors for this article] (2001). Health-Related Quality of Life in Multiple Myeloma Patients Receiving High-Dose Chemotherapy with Autologous Blood Stem-Cell Support. Medical Oncology (MO). ISSN 1357-0560. 18(1), p. 65–77.
• Wisløff, Finn; Tangen, Jon-Magnus; Brinch, Lorentz; Dahl, Inger-Marie; Hammerstrøm, Jens & Waage, Anders [Show all 8 contributors for this article] (2001). High dose therapy with autologous stem cell support - finally a progress in myelomatosis. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 121(20), p. 2402–2406.
• Jacobsen, E.M.; Barna-Cler, Linda; Taylor, J.M.; Triplett, Douglas & Wisløff, Finn Georg B (2000). The Lupus Ratio test- an interlaboratory study on the detection of lupus anticoagulants by an APTT-based, integrated and semi-quantitative test. Thrombosis and Haemostasis. ISSN 0340-6245. 83, p. 704–708.
• Lenhoff, Stig; Hjorth, Martin; Holmberg, E.; Turesson, Ingemar; Westin, Jan & Wisløff, Finn Georg B [Show all 11 contributors for this article] (2000). Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population based study. Blood. ISSN 0006-4971. 95, p. 7–11.
• Wisløff, Finn Georg B & Gulbrandsen, Nina (2000). Health-related quality of life and patients' perceptions in interferon-treated multiple myeloma patients. Acta Oncologica. ISSN 0284-186X. 39, p. 809–813.
• Evensen, Stein A.; Brinch, Lorentz; Hammerstrøm, Jens; Wisløff, Finn Georg B & Waage, Anders (1999). Leukemi hos voksne. In Dahl, O; Christoffersen, Thoralf & Kvaløy, Stein (Ed.), Cytostatika. Den norske kreftforening, Oslo. p. 266–278.
• Ringdal, L; Ringdal, GI; Kaasa, Stein; Bjordal, Kristin; Wisløff, Finn Georg B & Sundstrøm, Stein [Show all 7 contributors for this article] (1999). Assessing the consistency of psychometric properties in the HRQOL scales within the EORTC-C30 across populations by means of the Mokken Scaling Model. Quality of Life Research. ISSN 0962-9343. 8, p. 25–43.
• Schjetlein, Rune; Abdelnoor, Michel; Haugen, Gunnar; Husby, Henrik; Sandset, Per Morten & Wisløff, Finn Georg B (1999). Hemostatic variables as independent predictors for fetal growth retardation in preeclampsia. Acta Obstetricia et Gynecologica Scandinavica. ISSN 0001-6349. 78, p. 191–197.
• Jacobsen, E.M.; Sandset, Per Morten & Wisløff, Finn Georg B (1999). Do antiphospholipid antibodies interfere with tissue factor pathway inhibitor? Thrombosis Research. ISSN 0049-3848. 94, p. 213–220.
• Stead, ML; Brown, JM; Velikova, G; Kaasa, Stein; Wisløff, Finn Georg B & Child, JA [Show all 10 contributors for this article] (1999). Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma. British Journal of Haematology. ISSN 0007-1048. 104, p. 605–611.
• Turesson, Ingemar; Abildgaard, N; Ahlgren, T; Dahl, I.M.S.; Holmberg, E. & Hjorth, Martin [Show all 12 contributors for this article] (1999). Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors. British Journal of Haematology. ISSN 0007-1048. 106, p. 1005–1012.
• Wisløff, Finn Georg B; Gulbrandsen, Nina & Nord, Erik (1999). Therapeutic options in the treatment of multiple myeloma. Pharmacoeconomic and quality of life considerations. PharmacoEconomics (Auckland). ISSN 1170-7690. 16, p. 329–341.
• Hjorth, Martin; Holmberg, E.; Rödjer, S; Turesson, Ingemar; Westin, Jan & Wisløff, Finn Georg B (1999). Survival in conventionally treated younger (<60 years) multiple myeloma patients: no improvement during two decades. European Journal of Haematology. ISSN 0902-4441. 62, p. 271–277.
• Ringdal, Kristen; Ringdal, Gerd Inger; Kaasa, Stein; Bjordal, Kristin; Wisløff, Finn & Sundstrøm, Stein Harald [Show all 7 contributors for this article] (1999). Assessing the consistency of psychometric properties of the HRQoL scales within the EORTC QLQ-C30 across populations by means of the Mokken Scaling Model. Quality of Life Research. ISSN 0962-9343. 8, p. 25–43.
• Moe, Narve & Wisløff, Finn Georg B (1998). Preeclampsia and fetal growth retardation: is there an association with antiphospholipid antibodies? Hypertension in Pregnancy. ISSN 1064-1955. 17, p. 81–92.
• Schjetlein, Rune; Abdelnoor, Michel; Haugen, Guttorm; Husby, Henrik; Sandset, Per Morten & Wisløff, Finn Georg B (1998). Hemostatic variables as independent predictors for fetal growth retardation in preeclampsia. Acta Obstetricia et Gynecologica Scandinavica. ISSN 0001-6349.
• Kaasa, Stein; Hjermstad, M. J.; Jordhøy, Marit S; Wisløff, Finn Georg B & Loge, Jon Håvard (1998). Compliance in quality of life data: A Norwegian experience. Statistics in Medicine. ISSN 0277-6715. 17, p. 623–632.
• Wisløff, Finn Georg B (1998). Effect of interferon on the health-related quality of life in multiple myeloma. Biotherapy in cancer. ISSN 1386-6060. 2, p. 38–42.
• Schjetlein, Rune; Haugen, Gunnar; Moe, Narve; Husby, Henrik & Wisløff, Finn Georg B (1998). Preeclampsia and fetal growth retardation: is there an association with antiphospholipid antibodies? Hypertension in Pregnancy. ISSN 1064-1955. 17, p. 81–92.
• Wisløff, Finn Georg B (1998). Measuring quality of life in multiple myeloma. Cancer research, therapy & control. ISSN 1064-0525. 6, p. 337–341.
• Djurovic, Srdjan; Schjetlein, Rune; Wisløff, Finn Georg B; Haugen, Gunnar & Berg, Kåre (1997). Increased levels of adhesion molecules ICAM-1, VCAM-1 in preeclampsia. British Journal of Obstetrics and Gynaecology. ISSN 0306-5456. 104, p. 466–470.
• Djurovic, Srdjan; Schjetlein, Rune; Wisløff, Finn Georg B; Haugen, Guttorm & Berg, Kåre (1997). Plasma concentrations of Lp(a)lipoprotein and TGF-beta 1 are altered in preeclampsia. Clinical Genetics. ISSN 0009-9163. 52, p. 371–376.
• Bach-Gansmo, Edvin; Strand, Øystein Anders; Godal, Hans Christian; Wisløff, Finn Georg B & Skjønsberg, Ole Henning (1997). Discrepancy between latex and ELISA D-dimer values in sepsis may be caused by human neutrophil elastase. Thrombosis and Haemostasis. ISSN 0340-6245. p. 544–544.
• Bach-Gansmo, Edvin; Strand, Øystein Anders; Godal, Hans Christian; Wisløff, Finn Georg B & Skjønsberg, Ole Henning (1997). Discrepancy between latex and ELISA D-dimer values in sepsis may be caused by human neutrophil elastase. Thrombosis Research. ISSN 0049-3848. 86(2), p. 141–152. Show summary

  Abstract We have recently shown that D-dimers are degraded by human neutrophil elastase (HNE) in vitro, causing rapid decrease in the D-dimer levels measured by a Latex test, but not with an ELISA test employing the same monoclonal antibody against D-dimer. To see if such discrepant D-dimer concentrations occurred in patients with high HNE concentration, we examined 80 plasma samples from 8 patients with sepsis with a Latex and an ELISA test and calculated the ratio between the D-dimer values obtained with the two tests. Twenty healthy pregnant and twenty pre-eclamptic patients, who are known to have raised D-dimer but low HNE concentrations, were chosen as controls. HNE levels were estimated by determining the HNE-alpha1-proteinase inhibitor complex (HNE-A1PI) concentration. HNE-A1PI concentration was increased in sepsis patients compared with pre-eclamptic patients (p<0.0005) and healthy pregnant women (p<0.0005). In sepsis patients, the D-dimer results were skewed towards lower ratios between Latex and ELISA values compared to pre-eclamptic patients (p=0.008) and healthy pregnant women (p=0.0001). In plasma samples from patients with the largest discrepancy between Latex and ELISA D-dimer values, Western blotting with immunostaining indicated degradation of D-dimers to D-like fragments similar to those observed following degradation of cross-linked fibrin by HNE in vitro. We conclude that in sepsis patients there is a marked discrepancy between Latex and ELISA D-dimer values that may be caused by HNE. In such patients Latex D-dimer assays may cause severe underestimation of fibrinolysis.

View all works in Cristin

• Wisløff, Finn Georg B & Fossum, Sigbjørn (2012). Forskning viser at ... Vurdering og formidling av medisinske forskningsresultater. Gyldendal Akademisk. ISBN 978-82-05-42551-4. 359 p.
• Finset, Arnstein; Wisløff, Finn Georg B; Jacobsen, Jørn E. & Fyrand, Live (2010). Utfordring og mulighet: en helsetjeneste i endring. Unipub forlag. ISBN 978-82-303-1552-1. 219 p.
• Evensen, Stein A.; Brinch, Lorentz; Tjønnfjord, Geir Erland & Wisløff, Finn Georg B (1999). Blodsykdommer. Universitetsforlaget. ISBN 82-00-42552-5. 294 p.
• Evensen, Stein A.; Brinch, Lorentz; Hammerstrøm, Jens; Wisløff, Finn & Waage, Anders (1999). Leukemi hos voksne. Institutt for farmakoterapi. Den norske kreftforening.

View all works in Cristin

• Smeland, Erlend B; Vartdal, Frode & Wisløff, Finn Georg B (2010). Tett samarbeid, men ikke overstyring. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 130(6), p. 590–591.
• Smeland, Erlend B; Vartdal, Frode & Wisløff, Finn Georg B (2010). Ledelse og akademisk kompetanse. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 130(6).
• Benestad, Haakon Breien & Wisløff, Finn Georg B (2008). Forskningsetikk og Universitetet i Oslo. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 128(15), p. 1683–1684.
• Sullivan, Daniel; Singhal, Seema; Schuster, Micael; Gimsing, Peter; Wisløff, Finn & Waage, Anders [Show all 11 contributors for this article] (2006). A phase II study of PDX 101 in advanced multiple myeloma.
• Wisløff, Finn Georg B (2003). The extent of skeletal disease and response to therapy are more important predictors for quality of life than haemoglobin levels in multiple myeloma.
• Wisløff, Finn Georg B (2003). Impact of age on survival after intensive therapy in newly diagnosed multiple myeloma.
• Wisløff, Finn Georg B (2003). Nordic Myeloma Study Group Guidelines on the diagnosis and management of multiple myeloma.
• Wisløff, Finn Georg B (2003). In multiple myeloma, the extent of skeletal disease and response to therapy are more important predictors for quality of life than haemoglobin levels.
• Standal, Therese; Børset, Magne; Lenhoff, S.; Wisløff, Finn; Størdal, Berit Fladval & Sundan, Anders [Show all 8 contributors for this article] (2002). Serum Insulin-Like Growth Factor Is Not Elevated in Patients with Multiple Myeloma but Is Still a Prognostic Factor.
• Liestøl, Sigurd & Wisløff, Finn Georg B (2002). Does subcutaneous administration of low molecular weight heparin cause false positive tests for lupus anticoagulant?
• Liestøl, Sigurd & Wisløff, Finn Georg B (2002). Does subcutaneous administration of low molecular weight heparin cause false positive tests for lupus anticoagulant?
• Jacobsen, Eva Marie; Trettenes, E.J.; Strekerud, F. G.; Wisløff, Finn Georg B & Abildgaard, Ulrich (2002). Lupus anticoagulant quantification in heparinized patients using addition of polybrene.
• Wisløff, Finn Georg B (2001). Bruk av blod fra hemokromatosepasienter. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 121, p. 1448–1448.
• Wisløff, Finn Georg B (2001). Quality of life and cost-utility in multiple myeloma: what have we learnt?
• Jacobsen, E.M. & Wisløff, Finn Georg B (2000). The interpretation of clotting times in the laboratory detection of lupus anticoagulants (LA).
• Jacobsen, E.M. & Wisløff, Finn Georg B (2000). Lupus Ratio: an international inter-laboratory study using an integrated test for lupus antiocoagulants (LA).
• Wisløff, Finn Georg B & Kierulf, Peter (1999). An aima: uten blod. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 119, p. 2801–2809.
• Wisløff, Finn Georg B (1998). Kvalitetssikring ved diagnostikk og behandling av blodsykdommer. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 118.
• Foss, Kari Bente; Øvstebø, Reidun; Joø, Gun Britt; Urdal, Petter; Sandset, Per Morten & Wisløff, Finn Georg B [Show all 7 contributors for this article] (1998). Genetisk hemokromatose - praktiske retningslinjer. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 118(12).
• Jacobsen, Eva Marie; Sandset, Per Morten & Wisløff, Finn Georg B (1997). Do antiphospholipid antibodies influence the intravascular levels of tissue factor pathway inhibitor (TFPI)?
• Abildgaard, Ulrich; Brosstad, Frank Roger; Evensen, Stein A.; Garberg, K.; Iversen, Ole-Erik & Nesheim, Britt Ingjerd [Show all 10 contributors for this article] (1997). Vurdering av trombosetendens før forskrivning av p-piller. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 117, p. 281–282.
• Kvam, Ann Kristin & Wisløff, Finn Georg B (2011). Health-related quality of life in patients with multiple myeloma : what makes a difference to the patient? Unipub forlag. ISSN 978-82-8264-137-1.

View all works in Cristin